96-29345. National Heart, Lung, and Blood Institute; Division of Lung Diseases, Phase II or Phase III Clinical Trails

[Federal Register Volume 61, Number 222 (Friday, November 15, 1996)]
[Notices]
[Page 58573]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-29345]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Heart, Lung, and Blood Institute; Division of Lung 
Diseases, Phase II or Phase III Clinical Trails

    The National Heart, Lung, and Blood Institute Acute Respiratory 
Distress Syndrome Network, a group of 10 academic medical centers 
consisting of 24 hospitals with expertise in clinical research relating 
to acute adult lung injury, invites letters of interest by December 1, 
1996 from private sector companies who have developed novel therapies 
for acute lung injury and/or acute respiratory distress syndrome (ARDS) 
and who are interested in collaborating in Phase II or Phase III 
clinical trials. Letters of interest will not be viewed as a formal 
commitment, but are invited as a first step in exploring possible 
future collaborations. Information submitted will be treated as 
strictly confidential. Letters of interest should include a proposal 
regarding the nature of possible interactions with the ARDS Network. 
Network investigators and NHLBI staff will select agents for study 
based on scientific interests, novelty, feasibility, and availability. 
It is anticipated that clinical trials of agents selected will be 
initiated as early as 1997, but later starting dates will also be 
considered. Letters should be sent by December 1, 1996 to Dorothy 
Berlin Gail, Ph.D., Director, Lung Biology and Disease Program, 
Division of Lung Diseases, NHLBI, 6701 Rockledge Drive Room 10100, 
Bethesda, Maryland 20892-7952.

    Dated: November 7, 1996.
Sheila E. Merritt,
Executive Officer, NHLBI.
[FR Doc. 96-29345 Filed 11-14-96; 8:45 am]
BILLING CODE 4140-01-M